Cargando…

Global improvement with cariprazine in the treatment of bipolar I disorder and schizophrenia: A pooled post hoc analysis

INTRODUCTION: Global rating scale measures are useful for assessing the clinical relevance of patient change. Cariprazine, a dopamine D(3) and D(2) receptor partial agonist, is FDA‐approved for the adult treatment of acute manic/mixed episodes of bipolar I disorder and schizophrenia. Post hoc evalua...

Descripción completa

Detalles Bibliográficos
Autores principales:	Durgam, Suresh, Earley, Willie, Lu, Kaifeng, Németh, György, Laszlovszky, István, Volk, Stephen, Litman, Robert E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Psychiatry
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5765496/ https://www.ncbi.nlm.nih.gov/pubmed/29119668 http://dx.doi.org/10.1111/ijcp.13037

Ejemplares similares

The safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis
por: Nasrallah, Henry A., et al.
Publicado: (2017)

Cariprazine in the treatment of schizophrenia: a proof-of-concept trial
por: Durgam, Suresh, et al.
Publicado: (2016)

Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II/III randomized, double-blind, placebo-controlled studies
por: Earley, Willie, et al.
Publicado: (2017)

Efficacy of adjunctive low-dose cariprazine in major depressive disorder: a randomized, double-blind, placebo-controlled trial
por: Fava, Maurizio, et al.
Publicado: (2018)

Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies
por: Barabássy, Ágota, et al.
Publicado: (2021)

Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week, single-arm, open-label extension study
por: Durgam, Suresh, et al.
Publicado: (2016)

Cariprazine Safety in Adolescents and the Elderly: Analyses of Clinical Study Data
por: Szatmári, Balázs, et al.
Publicado: (2020)

Cariprazine, A Broad-Spectrum Antipsychotic for the Treatment of Schizophrenia: Pharmacology, Efficacy, and Safety
por: Laszlovszky, István, et al.
Publicado: (2021)

Relationship Between Plasma Concentrations and Clinical Effects of Cariprazine in Patients With Schizophrenia or Bipolar Mania
por: Periclou, Antonia, et al.
Publicado: (2019)

Tolerability of cariprazine in the early stage of schizophrenia: A pooled, post-hoc analysis of 4 phase ii/iii double-blind placebo-controlled trials
por: Dombi, Z.B., et al.
Publicado: (2021)

Efficacy of cariprazine in bipolar I depression across patient characteristics: a post hoc analysis of pooled randomized, placebo-controlled studies
por: Patel, Mehul, et al.
Publicado: (2020)

Long-term safety and tolerability of cariprazine as adjunctive therapy in major depressive disorder
por: Vieta, Eduard, et al.
Publicado: (2019)

What Is the Minimum Clinically Important Change in Negative Symptoms of Schizophrenia? PANSS Based Post-hoc Analyses of a Phase III Clinical Trial
por: Czobor, Pál, et al.
Publicado: (2022)

Minimal Effects of Cariprazine on Prolactin Levels in Bipolar Disorder and Schizophrenia
por: Culpepper, Larry, et al.
Publicado: (2022)

The effect of cariprazine on patient engagement: Post-hoc analysis of a phase 3 study in patients with predominant negative symptoms of schizophrenia
por: Laszlovszky, I., et al.
Publicado: (2021)

Cariprazine efficacy in bipolar I depression with and without concurrent manic symptoms: post hoc analysis of 3 randomized, placebo-controlled studies
por: McIntyre, Roger S., et al.
Publicado: (2020)

Cariprazine’s efficacy in treating affective symptoms – pooled data from schizophrenia and bipolar depression trials
por: Mcintyre, R., et al.
Publicado: (2022)

Linking PANSS negative symptom scores with the Clinical Global Impressions Scale: understanding negative symptom scores in schizophrenia
por: Leucht, Stefan, et al.
Publicado: (2019)

Cariprazine’s efficacy in treating depressive symptoms – pooled data from schizophrenia, bipolar depression and major depression trials
por: McIntyre, R. S., et al.
Publicado: (2023)

Case series: Cariprazine in early-onset schizophrenia
por: Ivanova, Elena, et al.
Publicado: (2023)

Cariprazine in the Treatment of Bipolar Disorder: Within and Beyond Clinical Trials
por: Do, André, et al.
Publicado: (2021)

Safety during polypharmacy: A post-hoc analysis examining the safety profile of cariprazine with other antipsychotics in the cross-titration phase
por: Vass, G., et al.
Publicado: (2021)

The efficacy of cariprazine in chronic schizophrenia – post hoc analyses of phase II/III clinical trials
por: Falkai, P., et al.
Publicado: (2022)

Update on schizophrenia and bipolar disorder: focus on cariprazine
por: Roberts, Rona Jeannie, et al.
Publicado: (2016)

Dosing Cariprazine Within and Beyond Clinical Trials: Recommendations for the Treatment of Schizophrenia
por: Rancans, Elmars, et al.
Publicado: (2022)

Cariprazine's Potential in Improving Social Dysfunction in Patients With Schizophrenia: A Perspective
por: Morozov, Petr, et al.
Publicado: (2022)

Treatment of Symptom Clusters in Schizophrenia, Bipolar Disorder and Major Depressive Disorder With the Dopamine D3/D2 Preferring Partial Agonist Cariprazine
por: Batinic, Borjanka, et al.
Publicado: (2021)

Evaluation of cariprazine in the treatment of bipolar I and II depression: a randomized, double-blind, placebo-controlled, phase 2 trial
por: Yatham, Lakshmi N., et al.
Publicado: (2020)

Case Report: Cariprazine in a Patient With Schizophrenia, Substance Abuse, and Cognitive Dysfunction
por: Rodriguez Cruz, Jose, et al.
Publicado: (2021)

Case Report: Cariprazine Efficacy in Young Patients Diagnosed With Schizophrenia With Predominantly Negative Symptoms
por: Vasiliu, Octavian
Publicado: (2021)

Case report: Treatment-resistant schizophrenia with auto-aggressive compulsive behavior—Successful management with cariprazine
por: Renemane, Lubova, et al.
Publicado: (2023)

Disentangling the symptoms of schizophrenia: Network analysis in acute phase patients and in patients with predominant negative symptoms
por: Demyttenaere, Koen, et al.
Publicado: (2021)

Efficacy and safety of cariprazine in bipolar I depression: A double‐blind, placebo‐controlled phase 3 study
por: Earley, Willie R., et al.
Publicado: (2019)

Case Report: Long-Acting Oral Cariprazine
por: Dyrmishi, Emanuela, et al.
Publicado: (2022)

New developments in the management of schizophrenia and bipolar disorder: potential use of cariprazine
por: Werner, Felix-Martin, et al.
Publicado: (2015)

Cariprazine hydrochloride for schizophrenia
Publicado: (2021)

Preferential binding to dopamine D(3) over D(2) receptors by cariprazine in patients with schizophrenia using PET with the D(3)/D(2) receptor ligand [(11)C]-(+)-PHNO
por: Girgis, Ragy R., et al.
Publicado: (2016)

Cariprazine Use in Early Psychosis: Three Case Reports
por: Coentre, Ricardo, et al.
Publicado: (2021)

Preclinical pharmacodynamic and pharmacokinetic characterization of the major metabolites of cariprazine
por: Kiss, Béla, et al.
Publicado: (2019)

Case report: Successful administration of cariprazine in a young, severely ill patient with recurrent relapses of schizophrenia and persistent negative symptoms
por: Vrublevska, Jelena
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_j4b4p5noo3u73jnj4pbpifh2qn